Congress to Clamp Down on Health Insurers' Sharply Higher Co-Pays?
-
Font Size:
The health insurance industry just can't seem to resist the urge to anger its policyholders and politicians, giving voters and politicians new reasons to clamp down on the industry's propensity to stick it to its sick customers in an effort to sell more insurance policies.
That the story about how insurers are making drug copays unaffordable for their chronically-ill patients is featured by NY Times means that Congress will rush to fix the problem one way or another. HMO stocks such as Coventry (CVH), Health Net (HNT), Humana (HUM), United Health (UNH) and Wellpoint (WLP) will be depressed even more, and drug companies' earnings and stocks will be depressed until the politicians deal with the issue.
As patients' non adherence to physicians' prescriptions grows due to the higher co-pays imposed by insurers, more will have to be admitted to hospitals, and insurers' non-pharmaceutical claims probably will soar. The NY Times reports that insurers have sharply increased co-pays on private and Medicare patients, making some of the most advanced drugs unaffordable. Impact graphs from the Times: With the new pricing system, insurers abandoned the traditional arrangement that has patients pay a fixed amount, like $10, $20 or $30 for a prescription, no matter what the drug’s actual cost. Instead, they are charging patients a percentage of the cost of certain high-priced drugs, usually 20 to 33 percent, which can amount to thousands of dollars a month.
The system means that the burden of expensive health care can now affect insured people, too. No one knows how many patients are affected, but hundreds of drugs are priced this new way. They are used to treat diseases that may be fairly common, including multiple sclerosis, rheumatoid arthritis, hemophilia, hepatitis C and some cancers. There are no cheaper equivalents for these drugs, so patients are forced to pay the price or do without. Insurers say the new system keeps everyone’s premiums down at a time when some of the most innovative and promising new treatments for conditions like cancer and rheumatoid arthritis and multiple sclerosis can cost $100,000 and more a year.
But the result is that patients may have to spend more for a drug than they pay for their mortgages, more, in some cases, than their monthly incomes.
Disclosure: none
Get Seeking Alpha Free Stock Alerts by Email!
Get Free Stock Alerts by Email!
ETFs In Focus
-
Editor's Picks
-
Most Popular
- Hedge Fund Manager's Notebook: Blood on the Streets - Buy Russia
- Reevaluating Coal
- Interview with Jim Rogers, Part II: China as World’s Best Long-Term Profit Play
- How You Can Invest in the Pickens Plan
- The Twin I-Beams of Investment Success
- On SLV's 10-for-1 Split: It's All About Liquidity
- Full list of Editor's Picks »
- The Disconnect Between Supply and Demand in Gold & Silver Markets »
- The Great Consumer Crash of 2009 »
- Petrobras: Buy and Sit Tight Like Soros »
- Jim Cramer's Unnecessary Beating Over Sirius »
- 5 Impressive Stocks in This Difficult Market »
- Wall Street Breakfast: Must-Know News »
- How You Can Invest in the Pickens Plan »
- Wall Street Breakfast: Must-Know News »
- Wall Street Breakfast: Must-Know News »
- Interview with Jim Rogers, Part I: Bigger Financial Shocks Loom »
- Apple Surge Expected - RBC »
-
Long Ideas
-
Short Ideas
-
Cramer's Picks
- Lehman Upgrade? - Fast Money Midday Recap (8/21/08)
- Kirkland Lake Gold: Buried Potential
- Seven High-Priced Stock Values
- Support for Freddie - Fast Money Recap (8/20/08)
- Why Thornburg Mortgage Will Survive
- How You Can Invest in the Pickens Plan
- Silver ETF Bull Market Remains Intact
- Making Sense of Fortuna Silver's Recent PPS Action
- Five Struggling Dividend Stocks I'm Still Bullish On
- Four Unique Oil Sands Plays You've Never Heard Of
- Full list of Long Ideas »
- Salesforce.com: It's All About the Guidance
- Three Casino Stocks Rolling Over
- New Web Site For Short Sellers: You Gotta Love Capitalism
- Commodity Carnage: Where to Turn Next?
- Fannie and Freddie Shareholders Run for the Exit
- Goldman: Readying Short Position Initiation Sequence
- Apple: Great Company with Lofty Valuation - Due for Pullback
- Russia's Too Risky - Barron's
- Fannie, Freddie Shareholders Will Be Left Holding the Bag - Barron's
- Pilgrim's Pride: The Weakest Link in the Food Chain
- Full list of Short Ideas »
- Alarming Negativity - Cramer's Mad Midday (8/21/08)
- Hershey vs. Cadbury - Cramer's Mad Money (8/20/08)
- Cheap Oil Related Stocks - Cramer's Lightning Round (8/20/08)
- Real Buys - Cramer's Mad Midday (8/20/08)
- Coke vs. Pepsi - Cramer's Mad Money (8/19/08)
- Clean Energy - Cramer's Lightning Round (8/19/08)
- Still Growing - Cramer's Mad Midday (8/19/08)
- Which Stock to Pick - Cramer's Mad Money (8/18/08)
- Buy Weyerhauser - Cramer's Lightning Round (8/18/08)
- The Price of Oil - Cramer's Mad Money (8/18/08)
- Full list of Cramers Picks »
Trading Center
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »



This article has 4 comments:
The supposition that this will cause more inpatiant care has obviously been thought through by the insuance companies and if they have estimated wrong it will be to their advantage to change.
Government heathcare has not worked anywhere in the world and anyone who thinks they will get more care at less cost from the government has not studied the results of political management of healthcare or any other industry.
Almost all those expensive drugs that are available to us have been developed in the USA.
Congress' solution will surely not be the one that makes the most sense. But the industry plan is probably to sit back, wait for Congress to act and then hope they can derail that action.
The industry should spearhead solutions.